references - shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/10034/14/15_references.pdf ·...
Post on 08-Mar-2018
219 Views
Preview:
TRANSCRIPT
REFERENCES
1. A. Kondo, (Ed.), in; Microcapsule Processing and Technology, Marcel Dekker, Inc.,
New York, 18, 1979.
2. M.H.Gutcho, (Ed.), in; Microcapsules and Microencapsulation Techniques, Noyes
Data Corporation, New Jersey, 236, 1976.
3. In: Joel Hardman and Lee Limbird, Eds., Goodman and Gilman’s; The Pharmacological
Basis of Therapeutics, 9th
Edn, McGraw-Hill, New york, 1484, 1996.
4. Laurence L.B, John S.L, Keith L.P., Goodman and Gilman’s; The Pharmacological
Basis of Therapeutics, 11th
Edn, McGraw-Hill, New york, 1639-1640, 2006.
5. Ballard, B.E., “An overview of prolonged action drug dosage forms. In: Robinson, J.R.
(Ed). Sustained and controlled release drug delivery systems”, Marcel Dekker, Inc.
New York. pp: 501-528, 1978.
6. Vyas, S. P. and Roop, K. Khar., “Controlled Drug Delivery: Concepts and Advances”,
1st Edition. 258, 2004.
7. Kondo A., Valkenburg, J.W.V., Eds., In; “Microcapsules Processing and Technology”
Marcel Dekker, New York, 32, 1979.
8. Bhalla, H.L. and Menon, M.D., “Long-acting microcapsules of pyrimethamine for
chemoprophylaxis of malaria”, Indian Drugs, 35, 705, 1998.
9. Barik, B.B., Gupta, B.K. and Pal, M., “Preparation and evaluation of rifampicin
microspheres”, Indian J. Pharm. Sci., 59, 110, 1997.
10. Chen, X.M., Ao, B.C. and Xin, J.F., “Medicinal values of neutraceuticals and foods”.,
J. China Pharmacy, 6, 7, 1995.
11. Pitchai Mani, R. and Shirwaikar, A.A., “Sustained-release matrix tablets”, Indian J.
Pharm. Sci., 57, 105, 1995.
12. Nimmannit and Sumanpatra, N., ”Microencapsulation technology and its applications”.,
J. Microencapsul., 13, 643, 1996.
13. Yoncheva, K., Lambov, N. “Development of biodegradable poly (α-methylmalate)
microspheres”, Die Pharmazie, 55, (2), 148-150, 2000.
14. Vachon, M.G. and Nairn, J.G., ”The influence of microencapsulation using Eudragit
RS100 on the hydrolysis kinetics of acetylsalicylic acid”., J. Microencapsul., 14, 281,
1997.
15. Tirkkonen, S., Urtti, A. and Paronen, P., ”The influence of microencapsulation using
Eudragit RS100 on the hydrolysis kinetics of acetylsalicylic acid”., Int. J. Pharm., 124,
219, 1995.
16. Mohsen, A. and Bayomi M., “Aqueous preparation and evaluation of albumin chitosan
microspheres containing Indomethacin”, Drug Dev. Ind. Pharm., 2004, 30(4), 329-339.
17. Kakkar, A.P., “The solubility of nutrients of the substrates and the low degree of
swelling” Eastern Pharmacist, 39, 129, 1996.
18. Chowdhury, S.R., Mukherjee, P.K., Singha, D., Ghosh, L.K. and Pal, M., “Quality
control and standardization of natural products formulation”, Eastern Pharmacist, 38,
137, 1995.
19. Sarry, E.M. and Abdel Zaher, A.O., “Pharmaceutical applications of cyclodextrins”, Bull.
Pharm. Sci., 19, 1, 1996.
20. Rafiee,T. M. and Sadegh, S. N., “Effect of polymers on formulation of controlled release
tablets”., Drug Ind. Pharm., 21, 1193, 1995.
21. An, Z., Lu, G., Mohwald, H. and Li, J., “The molecular level. In this paper we highlight
the recent trends in the electrochemistry of LbL films”, J. Chemistry, 11, 121, 2004.
22. Ichikawa, H., Fukumori, Y. and Moji Adeye, C., “Crosslinked chitosan microspheres for
encapsulation of Diclofenac sodium”, Int. J. Pharm., 156, 39, 1997.
23. Palomo, M.E., Ballesteros, M.P. and Frutos, P., “Diclofenac Sodium Microcapsules: In
Vitro Testing Considerations”, Drug Dev. Ind. Pharm., 23, 273, 1997.
24. Chowdary, K.P.R. and Sastry, V.H., “Microencapsulation of diclofenac”, Eastern
Pharmacist, 40, 119, 1997.
25. Rani, S.H.R., Nargund, L.V. and Prakasam, K., “Formulation and evaluation of
conventional, herbal and novel drug delivery” Indian Drugs, 33, 615, 1996.
26. Khopade, A.J. and Jain, N.K., “Self-assembling nanostructures for sustained ophthalmic
drug delivery”, Pharmazie, 50, 812, 1995.
27. Biju, S.S., Saisivam, S., Rajan, N.S. and Mishra, P.R., “Microencapsulation of
Diclofenac”, Eur. J. Pharm. Biopharm., 58(1), 61, 2004.
28. Akbuga, J. and Bergisadi, N., “Permeation rate of ketoprofen from poloxamer based
bioadhesive”, Drug Dev. Ind. Pharm., 23, 407, 1997.
29. Mandal, M. and Gupta, B.K., “Engineered erythrocytes as a drug delivery system”
Indian J. Pharm. Sci., 59, 181, 1997.
30. Palmieri, G.F., Martell, S., Lauri, D. and Wehrle, P., “Gelatin-acacia complex
coacervation as a method for ketoprofen microencapsulation”, Drug Dev. Ind. Pharm.,
22, 951, 1996.
31. Ricci, M., Blasi, P., Giovagnoli, S., Rossi, S., Macchiarulo, G., Luca, G., Basta, G. and
Calafiore, R., “Solid dispersions of Ketoprofen”., J. Controlled Release, 107(3), 395,
2005.
32. Habib, M.J. and Mesue, R., “Development of controlled release formulations of
ketoprofen for oral use”, Drug Dev. Ind. Pharm., 21, 1463, 1995.
33. Ugwoke, M.I., Verbeke, N. and Kinget, R., “Microencapsulation of apomorphine HCl
with gelatin”. Int. J. Pharm., 148, 23, 1997.
34. Pollock DK, Sheskey PJ., “Micronized ethylcellulose: opportunities in direct-
compression controlled-release tablets”. Pharm Technol. 1996;20:120–130
35. Amperiadou A, Georgarakis M., “Controlled release salbutamol sulphate microcapsules
prepared by emulsion solvent-evaporation technique and study on the release affected
parameters”. Int J Pharm. 1995; 115:1–8.
36. Nagarajan, M., Ganesan, M. and Nalluri, B.N., “Experimental efficacy of targeting PEG-
liposomes encapsulation techniques”, Eastern Pharmacist, 39, 123, 1996.
37. Narisawa, S., Nagata, M., Hirakawa, Y., Kobayashi, M. and Yoshino, H., “Permeability
enhancement of Eudragit RS coating led by physicochemical interactions with organic
acid”, J. Pharm. Sci., 85, 184, 1996.
38. Donbrow, M., Hoffman, A. and Benita, S., “Gradation of microcapsule wall porosity by
deposition of polymer mixtures (Eudragit RL and Eudragit RS)”., J. Microencapsul., 12,
273, 1995.
39. Phuapradit, W., Shah, N.H., Railkar., Williams, L. and Infield, M.H., “In vitro
characterization of polymeric membrane used for controlled release application”. Drug
Dev. Ind. Pharm. 21:955–963. (1995).
40. Badawi, A.A., El-Samaligy, M., Badawi, S.S. and Aziz, R.L., “Controlled release
theophylline delivery systems using Eudragit RS 100”, Pharmazie, 53, 556, 1998.
41. Yao, T., Yamada, M., Yamahara, H. and Yoshida, M., “Tableting of coated particles",
Chem. Pharm. Bull., 46, 826, 1998.
42. Amperiadou, A. and Georgarakis, M., “The emulsion-solvent evaporation technique”,
Drug Dev. Ind. Pharm., 21, 1339, 1995.
43. Valleri, M and Mura, P., “Factors influencing the release of aminophylline from tableted
ethylcellulose microcapsules”, Drug Dev. Ind. Pharm., 21, 2139, 1995.
44. Chowdary, K.P.R. and Girijasankar, G., “Eudragit microcapsules of nifedipine” Drug
Dev. Ind. Pharm., 23, 331, 1997.
45. Antal. I., Zelko, R., Roczey, N., Plachy, J. and Racz, I., “Dissolution and diffuse
reflectance character- istics of coated theophylline particles”. Int. J. Pharm., 55, 83,
1997.
46. Chowdary, K.P.R., Nagarajan, M. and Nalluri, B.N., “Microencapsulation of nifedipine-
MCC solvent deposited system for sustained release”, Indian J. Pharm. Sci., 58, 152,
1996.
47. Yuksel N, Kanık AE, Baykara T. “Comparison of in vitro dissolution profiles by
ANOVA-based model-dependent and independent methods”, Int J Pharm. 2000;
209:57–67.
48. Yuksel, N., Tincer, T. and Baykara, T., “Interaction between nicardipine hydrochloride
for a controlled release system”, Int. J. Pharm., 140, 145, 1996.
49. Gohel, M.C. and Patel, M.M., “Studies in Pellet Preparation and Development of
Modified Release dosage form of Isosorbide Nitrate”, Eastern Pharmacist, 39, 133,
1996.
50. Jayaswal SB, Reddy TSR, Vijay Kumar Gupta. “Preparation and Evaluation of Captopril
microspheres by spherical crystallization”, Indian Drugs. 1995; 32(9):454-57.
51. Kristmundsdottir, T., Gudmundsson, O.S. and Ingvarsdottir, K., “Release of Diltiazem
from. Eudragit microparticles prepared by spray drying”, Int. J. Pharm., 137, 159, 1996.
52. Jones, D.S. and Pearce, K.J., “Investigation of the effects of some process variables on
microencapsulation of propranolol HCl by solvent evaporation method”, Int. J. Pharm.,
118, 199, 1995.
53. Kala, V., Dabre, R., Bhusari, K. P. “A new approach to formulation of lactobacilli used as probiotic
and antidiarrhoa agent”, Indian Drugs. 35, 281-285, 1998.
54. Prakash and Satya., “In-vitro analysis of APA microcapsules for oral delivery of live
bacterial cells”, J Microencapsul., 2005; 22(5):539-547.
55. Samanta K.M., Tamilvanan S., Babu K., Suresh B., “Formulation and Evaluation of
Chlorpromazine Hydrochloride Loaded Self-Cross-Linked Gelatin Microcapsules”,
Indian J. Pharm. Sci., 59. 68, 1997.
56. Dutta, U.K. and Ghosal, S.K., “Targetting drug delivery system”, Indian Drugs, 32, 484,
1995.
57. Ndesendo, V.M.K. and Meixner, W., “Comparison between the Bioadhesivity Potential
of Two Novel Polymer-Based Matrices for Intravaginal Drug Delivery”. J.
Microencapsul., 13, 1, 1996.
58. Shettiger, R. and Damle, A.V., “Controlled release pellets of isoxsuprine hydrochloride”
.Indian J. Pharm. Sci., 57, 210, 1995.
59. Tang, H. Q., Jiang, W. L., Zhao, G.H. and Zou, L. J. “Traditional Chinese Medicine” ,
Chinese J. Pharm., 27, 11, 1996.
60. Tuncel, T., Bergisadi, N., Akin, L., Otuk, G. and Kuscu, I., “ In vitro and. In vivo studies
on microcapsules and tabletted microcapsules of cephradine”, Pharmazie, 51, 168, 1996.
61. Kondo, T., Hafez, E., Abdel-Monem, H., EI-Harras, S. and EI-Gibaly, I. et al.,
“Characterization of Piroxicam-cyclodextrins Inclusion”, Pharmazeutische Industrie,
58, 552, 1996.
62. Tomoaki, Y., Machida, Y., Hiraku, O. and Nagai, T., “Development and characterization
of rifampicin loaded floating microspheres”. Drug Dev. Ind. Pharm., 29, 417, 2003.
63. Stevens, W.F, “Chitosan-alginate multilayer beads for gastric passage and controlled
intestinal release of protein”, Drug Dev. Ind.Pharm.2003, 29, 713-724.
64. Zhao, Y., Chen, W., Cai, Q., Wang, S., Bo. J. and Wu, C., “Erosion Induced Controllable
Release of Gliclazide Encapsulated Inside Degradable Polymeric Particles”, Macromol.
Biosci., 4(3), 308, 2004.
65. Asrar, J., Ding, Y., La Monica, R.E. and Ness, L.C., “Controlled release of tebuconazole
from a polymer matrix microparticle: release kinetics and length of efficacy”. J. Agric.
Food Chem., 52(15), 4814, 2004.
66. Portero, A., Remunan-Lopez, C., Criado, M.T. and Alonso, M. J., “Preparation of
reacetylated chitosan microspheres with suitable properties for the controlled release of
active anti-microbial agents, such as amoxycillin and metronidazole, in the gastric
cavity”. J. Microencapsul., 19(6), 797, 2002.
67. Mandal, T.K., Bostanian, L.A., Graves, R.A., Chapman, S.R. and Womack, “A
biodegradable, orally active controlled-release formulation of amifostine”, Drug Dev.
Ind. Pharm., 28(3), 339, 2002.
68. Ozalp, Y., Ozdemir, N., Kocagoz, S. and Hasirci, V., “Controlled release of vancomycin
from biodegradable microcapsules”. J. Microencapsul., 18(1), 89, 2001.
69. Nettey H., Haswani D., D’Souza M., Oettinger C. “In-vitro anti-microbial effect of encapsulated
vancomycin on internalized Staph. Aureus within endothelial cells”. Drug Development and
Industrial Pharmacy, 33 (2): 133-9, 2007.
70. Hombreio-Perez, M., Siepmonn, J., Zinuti, C., Lamprecht, A., Ubrich, N., Hoftman, M.,
Bodmeier, and Maincent, P., “Non-degradable microparticles containing a hydrophilic or
a lipophilic drug: preparation, characterization and drug release modeling”, J. Controlled
Release, 88, 413, 2003.
71. Kevin A., Jones, M.P., Fresneau, A.M., Angels, F. and Maria, J.A., “Chitosan
nanoparticles as delivery systems for doxorubicin”, J. Controlled Release, 73, 255, 2001.
72. Dinesh B. Shenoy, Reshma J. D’Souza, Sandip B. Tiwari and N. Udupa., 2003. “Potential
application of polymeric microsphere suspension as subcutaneous depot for insulin”, Drug
Dev. Ind. Pharm., 29(5), 555-563
73. Agnihotri, S.A. and Aminabhavi, T.M., “Recent advances on Chitosan based micro and nano
particles in drug delivery”, J. Controlled Release, 28, 245, 2004.
74. Shi, X.Y. and Ton, T.W., “Preparation of chitosan/ethylcellulose complex of vitamin D2”,
Biomaterials, 23 (23), 4469, 2002.
75. Obeidat, W.M. and Price, J.C., “Theophylline microspheres were prepared by the emulsion-
solvent evaporation method using cellulose acetate butyrate (CAB381-20) and mixtures of
CAB381-20(R) and cellulose acetate phthalate”., J. Microencapsul., 21, 47, 2004.
76. Song, M., Li, N., Sun, S., Tiedt, L.R., Liebenberg, W. and de Villiers, M.M., “Microcapsules
prepared by emulsion solvent evaporation”, Farmaco., 60(3), 261, 2005.
77. Savolainen, M., Herder, J., Khoo, C., Lorgvist, K., Dahigvist, C., Glad, H. and Juppo, A.M.,
“Controlled-release tablets of poorly-soluble drug felodipine”., Int. J. Pharm., 27, 47, 2003.
78. Assimopoulou, A.N. and Papageorgiou, V.P., “Preparation and release studies of alkannin-
containing microcapsules”, J. Microencapsul., 21(2), 161, 2004.
79. Pedersen, J.L., Lilleso, J., Hammer, N.A., Werner, M.U., Holte, K., Lacouture, P.G. and Kehlet,
H., “Bupivacaine in microcapsules prolongs analgesia after subcutaneous”, J. Anesth. Analg.,
99, 912, 2004.
80. Wang, H. J., Li, X.R., Huang, Y.Q., Zhang, Y.L., Hu, X. and Liu, Y., “Invivo and Invitro
Pharmaceutical behavior of lycopene microcapsules”.,Yao Xue Xue Bao., 40(9), 787, 2005.
81. Pargaonkar, N., Lvov, Y.M., Li, N., Steenekamp, J.H. and de Villiers, M.M., “Controlled release
of dexamethasone from microcapsules”, Pharm. Res., 22(5), 826, 2005.
82. Mukherjee, B., Mahanti, B., Panda, P. and Mahapatra, S., “Preparation and evaluation of
verapamil hydrochloride microcapsules”, American J. Therapeutics, 12(5), 417, 2005.
83. Yasmeen, R., Shoaib, M.H. and Khalid, H., “Comparative Study of Different Formulations of.
Atenolol”, Pak. J. Pharm. Sci., 18, 47, 2005.
84. Rao, K.R., Senapati, P.and Das, M.K., “Formulation and in vitro evaluation of ethyl cellulose
microspheres containing zidovudine”, J. Microencapsul., 22, 863, 2005.
85. Budhian, A., Siegel, S.J. and Winey, K.I., “Production of haloperidol-loaded PLGA nanoparticles
for extended controlled drug release of haloperidol”, J. Microencapsul., 22, 773, 2005.
86. Persyn, J.T., McDonough, J. A., Nino, J. A., Dixon, H. and Boland, E.J., “Use of
microencapsulation technology in combination with absorption”, J. Microencapsul., 22, 737,
2005.
87. Yuan, X.J., Zhang, Z.R., Song, Q.G. and He, Q., “Mucosal delivery of cytotoxic therapeutic
agents: response of rat nasal mucosa to microencapsulated ethopropazine HCl enantiome”,
Arch. Pharm. Res., 29, 795, 2006.
88. Yang, G.M., Kuo, J.F. and Woo, E.M., “Preparation and control-release kinetics of isosorbide
dinitrate microspheres”. J. Microencapsul., 23, 622, 2006.
89. Govender, S., Lutchman, D., Pillay, V., Chetty, D.J. and Govender, T., “Enhancing drug
incorporation into tetracycline-loaded chitosan microspheres for periodontal therapy”,
Microencapsul., 23, 750, 2006.
90. Das, M.K. and Rao, K.R., “Microencapsulation of Zidovudine by double emulsion solvent
evaporation method”., Acta. Pol. Pharm., 63, 141, 2006.
91. Homar, M., Ubrich, N. E., Ghazouani, F., Kristl, J., Kerc, J. and Maincent, P., “Influence of
polymers on the bioavailability of microencapsulated celecoxib” J. Microencapsul, 24, 621,
2007.
92. Schaffazick, S.R., Pohlmann, A.R.and Guterres, S.S., “Nanocapsules, nanoemulsion and
nanodispersion containing melatonin: preparation, characterization and stability
evaluation”, Pharmazie, 62, 354, 2007.
93. Jackson, J.K., Hung, T., Letchford, K. and Burt, H.M., 13. “The characterization of paclitaxel-
loaded microspheres manufactured from blends of poly (lactic-co-glycolic acid) (PLGA) and
low molecular weight diblock copolymers”, Int. J. Pharm., 342, 6, 2007.
94. Kar, M. and Choudhury, P.K., “Formulation and evaluation of ethyl cellulose microspheres
prepared by the multiple emulsion technique” Pharmazie, 62, 122, 2007.
95. Giovagnoli, S., Blasi, P., Schoubben, A., Rossi, C. and Ricci, M., “Preparation of large porous
biodegradable microspheres by using a simple double-emulsion method for capreomycin
sulfate pulmonary delivery”, Int. J. Pharm., 333 (2007), pp. 103–111
96. Jaspart, S., Bertholet, P., Piel, G., Dogne, J.M., Delattre, L. and Evrard, B., “Pulmonary drug
delivery”, Eur. J. Pharm. Biopharm., 65, 47, 2007.
97. Gal, A. and Nussinovitch. A., “Hydrocolloid carriers with filler inclusion for diltiazem
hydrochloride release”, J. Pharm. Sci., 96, 168, 2007.
98. Amitava, G., Uday Kumar, N., Prasant, R., Tanusree, N. and Partha, R., “Preparation and
Evaluation and invitro-invivo correlation (IVIVC) study of lamivudine loaded microspears”.,
Research J. Pharm. and Tech., 1(4), 353, 2008.
99. Rajinikanth, P. S., Karunagaran, L. N., Balasubramaniam, J. and Mishra,“ Formulation and
evaluation of clarithromycin microspears for eradication of H.Pylori”., Chem. Pharm. Bull.,
56(12), 1658, 2008.
100. Bhabani Shankar, N., Uday kumar, N., Balakrishna, K. P. and Prasant kumar, R.,
“Design and Evaluation of Controlled Release Bhara Gum Microcapsules of
Famotidine for Oral Use”, Research J. Pharm. and Tech., 1(4), 433, 2008.
101. Sah, H., Toddywala, R. and Chien, Y.W., “Continuous release of proteins from biodegradable
microcapsules and in vivo evaluation”, J. Controlled Release, 35, 137, 1995.
102. Uchida, T., Shiosaki, K., Nukada, Y., Fukada, K. and Matsuyama, K. et al., “Microencapsulation
of hepatitis B core antigen for vaccine preparation”, Pharma. Res., 15, 1708, 1998.
103. Haque, T., Chen, H., Ouyang, W., Martoni, C., Lawuyi, B., Urbanska, A.M. and Prakash,
S.,”Advances in Regenerative Medicine: Role of Nanotechnology, and Engineering”,
Biotechnol. Lett., 27(5), 317, 2005.
104. Bittner, B., Morlock, M., Koll, H., Winter, G. and Kissel, T., “Recombinant human
erythropoietin (rhEPO) loaded poly (lactide-co-glycolide) microspheres: influence of the
encapsulation technique and polymer purity on microsphere characteristics”, Eur. J. Pharm.
Biopharm., 45, 295, 1998.
105. Pean, J.M., Venier-Julienne, M.C., Boury, F., Menei, P. and Benoit, J.P. et. al., “NGF release
from poly (-lactide-co-glycolide) microspheres”, J. Controlled Release, 56, 175, 1998.
106. Cleland JL, Jones AJ. “Stable formulations of recombinant human growth hormone and
interferon-gamma for microencapsulation in biodegradable microspheres”. Pharm Res 1996;
13:1464–75.
107. Hermann, J. and Bodmeier, R., “The effect of particle microstructure on the somatostatin
release from poly (lactide) microspheres”, Int. J. Pharm., 126, 129, 1998.
108. Kovacs-Nolan, J. and Mine, Y., “Microencapsulation for the gastric passage and controlled
intestinal release of immunoglobulin”, J. Immunological. Methods, 296(1-2), 199, 2005.
109. Thomas, T.T., Kohane, D.S., Wang, A. and Langer, R., “Microparticulate formulations for the
controlled release of interleukin-2”, J. Pharm. Sci., 93 (5), 1100, 2004.
110. Holland, T.A., Tabata, Y. and Mikos, A.G., “In vitro release of transforming growth factor-beta
1 from gelatin microparticles encapsulated in biodegradable, injectable oligo(poly(ethylene
glycol) fumarate) hydrogels”., J. Controlled Release, 91(3), 299, 2003.
111. Takada, S., Yamagata, Y., Misaki, M., Taira, K. and Kurokawa, T., “Controlled-release
formulations of recombinant human growth hormone (rhGH)”, J. Controlled Release, 88(2),
229, 2003.
112. Singh, M., Singh, O. and Talwar, G.P., “Biodegradable delivery system for a birth control
vaccine”, Pharm. Res., 12, 1796, 1995.
113. Azarnia, S., Lee, B.H., Robert, N. and Champagne, C.P., “Microencapsulation of a recombinant
aminopeptidase (PepN) from Lactobacillus”, J. Microencapsul., 25, 46, 2008.
114. Badkar, A.V., Smith, A.M., Eppstein, J.A.and Banga, A.K., “Delivery of Insulin Using
Microneedles In-Vivo”, Pharm. Res., 24, 1389, 2007.
115. Ho, J., Wang, H. and Forde, G. M., “Process considerations related to the microencapsulation
of plasmid DNA via ultrasonic atomization”, Biotechnol. Bioengg., 101(1), 172, 2008.
116. Nkansah, M. K., Tzeng, S. Y., Holdt, D. T. and Lavik, E. B., “Poly (lactic-co-glycolic acid)
nanospheres and microspheres”., Biotechnol. Bioengg., 100(5), 1010 , 2008.
117. Saravanakumar, A., Sunita, M., Madulika, P., Pavani, S., Chandu, A. N., Umesh, M.,
Kamalakannan, K. and Sivakumar, T., “Polylactic Acid Microspheres as A Potential Vaccine
Delivery System for the Tetanus Toxoid: Preparation and In Vitro Dissolution Study”. Research
J. Pharm. and Tech., 1(4), 453, 2008.
118. Jiang, W. and Schwendeman, S. P., “Stabilization of tetanus toxoid encapsulated in PLGA
microspheres”, Mol. Pharm., 5(5), 808, 2008.
119. Dorle, A.K. and Pathak, Y.V., “Effect of pH on the release characteristics of drugs”, Drug Dev.
Ind. Pharm., 14, 2557, 1998.
120. Dorle, A.K., ’Effect of hydrophobic binding on microencapsulating materials”, Indian J. Pharm.
Sci., 54, 10, 1992.
121. Chowdary, K.P.R. and Vijaya Ratna, J., Chowdary, K.P.R. and Vijaya Ratna, “Preparation and
evaluation of cellulose acetate microcapsules of theophylline”, Indian J. Pharm. Sci., 52, 279,
1990.
122. Chowdary, K.P.R. and Vijaya Ratna, J.,”Studies on micro encapsulation by cellulose acetate”,
Indian Drugs, 28, 361, 1991.
123. Chowdary, K.P.R. and Vijaya Ratna, J., “Preparation and evaluation of cellulose acetate
Diclofenac Microspheres”, Indian Drugs, 29, 494, 1992.
124. Chowdary K.P.R. and Ramesh, K.V.R.N.S., “Solid dispersion of nifedipine in combined carriers,
PVP-MCC and HPC-MCC”, Drug Dev. Ind. Pharm., 21, 1183, 1995.
125. El-Fahan, T.H. and Massoud, A.A., “Nanocapsules as carrier for oral peptide delivery”, J.
Controlled Release, 32, 279, 1994.
126. Gutierrez-Pauls, L., Gonzalez-Alvarez, I., Lareo, Barone, M., Gil-Alegre, M. E. And Torres-
Suarez, A.I., “Poly (epsilon-caprolactone) microparticles formed by the the emulsion-
evaporation method”, Pharmazie, 62, 864, 2007.
127. Vlugt-Wensink, K.D., de Vrueh, R., Gresnigt, M.G., Hoogerbrugge, C.M., van Buul-Offers, S.C.,
de Leede, L.G., Sterkman, L.G., Crommelin, D.J., Hennink, W.E. and Verrijk, R., “hGH dextran
microsphere formulation”, Pharm. Res., 24, 2239, 2007.
128. Schuidt, U. and Hunkeler, D., “Microencapsulation Techniques”, J. Microencapsul., 24, 1,
2007.
129. Kar, M. and Choudhury, “Formulation and evaluation of ethyl cellulose microspheres
prepared by the multiple emulsion techniques”, P.K., Pharmazie, 62, 122, 2007.
130. Berchane, N.S., Jebrail, F.F., Carson, K.H., Rice Ficht, A.C. and Andrews, M.J., “Diameter and
size distribution of PLG Microspears”., J. Microencapsul., 23, 539, 2006.
131. McCarron, P.A., Donnelly, R.F. and Marouf, W., “Celecoxib-loaded poly (D, L-lactide-co-
glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and
emulsification steps as part of the salting-out procedure”. J. Microencapsul., 23, 480, 2006.
132. Singh, B.N.and Kim, K.H., “Effects of divalent cations on drug encapsulation efficiency of
deacylated gellan gum”, J. Microencapsul., 22, 761, 2005.
133. Chowdary, K.P.R., Mohapatra, P. and Murali Krishna, M.N., “Evaluation of olibanum resin as
microencapsulating agent for controlled drug delivery”, Indian J. Pharm. Sci., 68, 497, 2006.
134. Chowdary, K.P.R. and Mohapatra, P., “Pharmacokinetic Evaluation of Natural Resin Coated
Microcapsule”, International J. Chemical Sciences, 4, 747, 2006.
135. Panos, I., Acosta, N. and Heras, A., “New drug delivery systems based on chitosan”, Curr. Drug
Discov. Technol., 5(4), 333, 2008.
136. Tamilvanan, S. and Sa, B., “Effect of production variables on the physical characteristics of
ibuprofen-loaded polystyrene microparticles”, PDA J. Pharm. Sci. Technol., 62(3), 177, 2008.
137. Singh, P., Desai, S. J., Simonelli, A. P. and Higuchi, W. I., “Role of wetting on the rate of drug
release from inert matrices”, J. Pharm. Sci., 57 (2), 217, 1968.
138. Nakagami, H., Keshikawa, T., Matsumura, M. and Tsukamoto, H., “Application of aqueous
suspen- sions and latex dispersions of water-insoluble polymers for tablet and granule
coatings”, Chem. Pharm. Bull., 39 (7), 1837, 1991.
139. Donbrow, M. and Friedman, M.,”Enhancement of Permeability of Ethyl Cellulose Films for
Drug Penetration”, J. Pharm. Pharmac., 27, 633, 1975.
140. Efentakis, M., Al-Hmoud, H., Buckton, G. and Rajan, Z., “The influence of surfactants on drug
release from hydrophobic matrix”., Int. J. Pharm., 70, 153, 1991.
141. Reaven, G.M., “The most recent National Health and Nutrition Examination Survey hormone in
older hypothyroid patients”, American J. Med., 75, 8, 1983.
142. Felinglos, M.N. and Lebovitz, H.E., “Safety and efficacy of glipizide”, American J. Med., 75, 60,
1983.
143. Lebovitz, H.E., “Clinical utility of oral hypoglycemic agents in the management of patients with
noninsulindependent diabetes mellitus”., American J. Med., 75, 94, 1983.
144. Kennedy, D.L., Piper, J.M. and Baum, C., “Trends in the use of oral hypoglycemic agents”,
Diabetes Care, 11, 558, 1988.
145. Gerich, J.E., “Oral hypoglycemic agents”, New England J. Med., 321, 1231, 1989.
146. Wahlin-Boll, E., Almer, L.O. and Melander, A., “Bioavailability, pharmacokinetics and effects of
glipizide in type 2 diabetics”, Clin. Pharmacokinetics, 7, 363, 1982.
147. Feldman, J.M. Glyburide: “A second generation sulfonylurea hypoglycemic agent”,
Pharmacotherapy, 5, 43, 1985.
148. Jaspan, J.B., Metabolism, “Effects of sorbinil therapy in diabetic”, 9; 149(46):3111-4, 1987.
149. Drentz, A.J., Ferner, R.E. and Bailey, C.J., “Comparative tolerability profiles of oral antidiabetic
agents”, Drug Safety, 11, 223-241, 1994.
150. Melander, A. and Wahlin-Boll, E., “Clinical pharmacology of glipizide”, American J. Med., 75, 41,
1983.
151. Lebovitz, H.E., “Glipizide: A second generation sulfonylurea hypoglycemic agent”
Pharmacotherapy, 5, 63, 1985.
152. Groop, L., Wahlin-Boll, E., Groop. P.H., Soterman, K.J., Melander, A., Tolppaner, E.M. and
Fyhrquist, F., Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2
diabetics, Eur. J. Clin. Pharmacol., 28, 697, 1985.
153. Ahren, B., Lundquist, I. And Schersten, B., “Effects of glipizide on various consecutive insulin
secretory stimulations in patients with type 2 diabetes”, Diabetes Research, 3, 293, 1986.
154. Melander, A., “Clinical pharmacology of sulfonylureas”, Metabolism, 38, 12, 1987.
155. Groop, P.H., Melander, A. and Groop, L.C., “The acute effect of preprandial exogenous and
endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in
patients with type 2 diabetes”, Diabet. Med., 10, 633, 1993.
156. Eisen, S.A., Miller, D.K., Woodward, R.S., Spitznazel, E. and Przybeck, T.R., “The effect of
prescribed daily dose frequency on patient medication compliance”, Arch. Internal Med.,
150(9):1881-4., 1990.
157. Botelho, R.J. and Dudrak, R.I.I., “Home assessment of adherence to long-term medicines in the
elderly”, J. Family Practice, 35, 61, 1992.
158. Pyorala, K., Unitupa, M., Laakso, M., Sitonen, O., Niskanen, L. and Ronnema, T., “Diabetes and
atherosclerosis: an epidemiologic view”, Diabetes Metabolism, 13, 345, 2000.
159. Stout, R.W., “Insulin and atheroma. 20-yr perspective”. Diabetes Care, 13, 631, 1990.
160. Font Bonne, A.M. and Eschwege, E.M.,”Insulin and cardiovascular disease. Paris Prospective
Study”, Diabetes Care, 14, 461, 1991.
161. Okhubu, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N.
and Shichiri, M., “Intensive insulin therapy prevents the progression of diabetic microvascular
complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized
prospective 6-year study”. Diabetes Res. Clin. Practice, 28, 103, 1995.
162. Berelowitz, M., Fischtte, C.T., Cefalu, W., Schade, D.S., Sutfin, T. and Kourides, I.A., “Comparative
efficacy of a once-daily controlled-release formulation of glipizide and immediate-release
glipizide in patients with NIDDM”, Diabetes Care, 17, 1460-64, 1994.
163. Berelowitz, M., Fischtte, C.T., Cefalu, W., Schade, D.S., Sutfin, T. and Kourides, I.A., “Comparative
efficacy of a once-daily controlled-release formulation of glipizide and immediate-release
glipizide in patients with NIDDM”, Diabetes Care, 17, 1460-64, 1994.
164. Simonson, D.C., Feinglos, M. and Shamon, H., “The Glipizide Gastrointestinal Therapeutic System
Study”, Diabetes Care, 20(4), 597, 1997.
165. Cefalu, W.T., Bell-Farrow, A.D., Wang, Z.Q., MC Bridge, D., Dalgleish, D. and Terry, T.G., “Effect
of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in
NIDDM”, Drug Development Research, 44, 1-7, 1998.
166. Physician Desk Reference (PDR), product information, Pfizer Inc., 54th Edn., Medical Economics
Company, 2000, 2008.
167. Foster, R.H. and Polsker, G.L., “A review of the pharmacoeconomic implications of the extended-
release formulation in type 2 diabetes mellitus”. Pharmacoeconomics, 18(3), 289, 2000.
168. Thombre, A.G., Denoto, A.R. and Gibbes, D.C., “Delivery of glipizide from asymmetric membrane
capsules using encapsulated excipients”, J. Controlled Release, 60, 333, 1999.
169. Garcia, J. and Ghaly, E.S., “Evaluation of bioadhesive glipizide spheres”., Pharm. Dev. And Tech.,
6, 407, 2001.
170. Verma, R.K. and Garg, S., “Development and evaluation of osmotically controlled oral drug
delivery system of glipizide”, Eur. J. Pharm. Biopharm., 57, 513, 2004.
171. Gan, Y., Pan, W., Wei, M. and Zhang, R., “Cyclodextrin complex osmotic tablet for glipizide
delivery”., Drug Dev. Ind. Pharm., 28, 1015, 2002.
172. Garcia. J. and Ghaly, E.S., “Evaluation of bioadhesive glipizide spheres and compacts from
spheres”, PR. Health Sci. J., 20(1), 25, 2001.
173. Chowdary, K.P.R. and Rao, Y.S., “Design and in vitro and in vivo evaluation of mucoadhesive
microcapsules of glipizide for oral controlled Release”., AAPS Pharm. Sci. Tech., 4(3), 320, 2003.
174. Dhawan, S., Singh, B., Garg, S.K., Hota, D., Dash, R.J., Singla, A.K. and Sinha, V.R., “Bioavailability
of immediate and Extend release formulations of glipizide in healthy male volunteer”, Clin.
Pharmacokinetics, 45(3), 317, 2006.
175. Sweetman, C.S., “Martindale the complete drug reference”, London, Pharmaceutical Press, 333,
2002.
176. Tripathi, K.D., “Essential of medical pharmacology”, New Delhi, Jaypee brother’s medical
publishers (p) ltd., 247-51, 2003.
177. Tan, M.H., Johns, D., Strand, J., Halse, J., Madsbad, S. and Eriksson, J.W., et al., “Sustained effect
of pioglitazone vs. glibenclamide on insulin sensitivity, glycemic control and lipid profile in
patient with type II diabetes”, Diabet Med., 21, 859 -866, 2004.
178. Anant, A., Rahul, T., Pandey, M. and Saraf, A.S., IPCA, 2009.
179. Wong, H., Ozalp, Y., Lainesse, A. and Alpan, R.S., “In vivo bioequivalence of oral antidiabetic
agents: pioglitazone tablets”, Arzneimittel-Forschung, 54(9A), 618-624, 2004.
180. Nagalakshmi, S. and Abdul Hasan Sathali, ”Sustained effect of pioglitazone Vs glibenclamide on
insulin sensitivity ,glycemic control and lipid profile in patients with type 2 diabetis” , The Indian
Pharmacist, New Delhi, 8, 57-66, 2009.
181. Singh, C., Jain, KA., Kumar, C., and Agarwal, K., “Design and invitro evaluation of mucoadhesive
microspheres of pioglitazone”, J. Young Pharma., 1(3), 195-198, 2009.
182. Wagner, J., Correlation of in vivo with in vitro data. Theoretical and practical
considerations., Deug. Intell. Clin.Pharm; 4: 32, 1970.
183. Noyes, A. A., and Whitney, W. R., The rate of solution of solid substances in their own
solutions. J. Ame. Chem. Soc; 19: 930., 1897.
184. Higuchi, W. I., Nir, N. A., and Desai, S. J., Dissolution-modulating mechanism of pH
modifiers in solid dispersion containing weakly acidic or basic drugs with poor water
solubility J. Pharm. Sci; 54: 1405., 1965.
185. Higuchi, T., and Ikeda, M., Letter: Rapidly dissolving forms of digoxin: hydroquinone
complex, J. Pharm. Sci, 63: 809, 1974.
186. Zogolio, M. A., Maulding, H. V., and Windheuser, J., Complexes of ergot alkaloids and
derivatives. I. The interaction of caffeine with ergotamine tartrate in aqueous solution, J.
Pharma. Sci; 1969, 58: 222.
187. Mullins, J. D., and Macek, T. J., Pharmaceutical applications of Polymorphism, J. Amer.
Pharm. Assoc; 1958, 47: 297.
188. Aguiar, A. J., Krc, J., Kinkel, A. W., and Samyn, J. C., Effect of Polymorphism on the
Absorption of Chloramphenicol from Chloramphenicol Palmitate, J. Pharm. Sci; 1967,
56: 847.
189. Moustafan, M. A., Khalil, S. A., Ebian, A. R., and Motawi, M. M., Preparation,
characterization, and interconversion of different crystal forms., J. Pharm. Sci; 1974,
63:1103.
190. Moustafan, M. A., Khalil, S. A., Ebian, A. R., and Motawi, M. M., Succinylsulfathiazole
crystal forms : Preparation, characterization, and interconversion of different crystal
forms.J. Pharm. Sci; 1975, 64:1481.
191. Hazratwala, B. R., and Taylor, B., dissolution studies on different dosage forms, J.
Pharma. Pharmacol; 1974, 28: 934.
192. Goyal, V. C., Kohil, D. V., and Upadhyay, R. K., Enhancement of solubility and
dissolution., Indian Drugs; 1982, 19: 233.
193. Sanghvi, N. M., and Jirani, N. J., A system for enhancing the water dissolution rate and
solubility of poorly soluble drugs. Indian Drugs; 1982, 19: 421.
194. Chiou, W. L., Chen, S. J., and Athanikar, N., Enhancement of dissolution rates of poorly
solubule drugs., J. Pharm. Sci; 1976, 65: 1702.
195. Poole, J. W., Own, G., Silvero, J., Freyhot, J. N., and Roseman, S. B., The absorption of
the anhydrous and trihydrate forms of ampicillin., Curr. Ther. Res; 1968, 10: 292.
196. Shefter, E., and Higuchi, T., Dissolution behavior of crystalline solvated, J. Pharm.
Assoc; 1958, 47: 297.
197. Leonard, J. R., The influence of solubility on the rate of gastrointestinal absorption of
aspirin, Clin. Pharmacol. Ther; 1963, 4: 476.
198. Truitt, E. B., and Morgan, A. M., Gastrointestinal factors in aspirin absorption. A
quantitative study. J. Pharm. Sci; 1964, 53: 129.
199. Javid, K. A., and Eadwallachr, D. E., Dissolution of aspirin from tablets containing
various buffering agents, J. Pharm. Sci; 1972, 61: 1370.
200. Nelson, E., Comparative dissolution rates of weak acid and their sodium salts, J. Pharm.
Sci; 1958, 47: 300.
201. Chowdary, K. P. R., and Srirama Murthy, A., Preparation and Evaluation of Glyceryl
Monostearate Microcapsules of Nitrofurantoin, 22; issue 525; Indian Drugs; 1985.
202. Wan, S. H., Pentikainen, P. J., and Azarnoff, D. L., Bioavailability of aminosalicylic acid
and its various salts in humans., J. Pharm. Sci; 1974, 63:708.
203. Nelson, E., Knoechel, E. L., Hamlin, W. E., and Wagner, J. G., Influence of the
absorption rate of tolbutamide., J. Pharm. Sci; 1962, 51: 509.
204. Nelson, E., Influence of dissolution rate and surface area on tetra- cycline absorption., J.
Amer. Pharm. Assoc. Sci. Ed; 1959, 48: 96.
205. Juncher, H., and Raschov, F., The solubility of oral preparations of penicillin-V.,
Antibiot. Med. Clin. Ther; 1957, 4: 497.
206. Nelson, E., Comparative dissolution rates of weak acids and their sodium salts, J. Amer.
Pharm. Assoc. Sci. Ed; 1958, 47: 297.
207. Vivino, E. A., Drugs solubility and rate, J. Phsrm.Sci; 1954, 43: 234.
208. Gagliani De Graff, A.C., and Kupperman, H.S., Enhanced theophylline blood levels
obtained after ingestion of choline theophyllinate as compared to aminophylline with or
without aluminum hydroxide Int. Rec. Med. Gen. Prac. Clin; 1954, 167: 251.
209. Daehne, W. V., Frederiksen, E., Gundersen, E., Lund, F., Morch, P., Peterson, H.J.,
Roholt, K., Tybring, L., and Godtfredsen, W. O., Acyloxymethyl esters of ampicillin., J.
Med. Chem; 1970, 13: 607.
210. Schwartz, M. A., and Hayton, W. L., Relative Stability of Hetacillin and Ampicillin in
Solution, J. Pharm. Sci; 1972, 61: 906.
211. Sinkula, A. A., Rationale for design of acid ester by the neighbouring dextran hydroxy
groups, Acta. Pharm. Suec; 1976, 7(13 Suppl)
212. Butter, K., English, A. R., Knirsch, A. K., and Korst, J. J.,Metabolism and laboratory
studies with indanyl carbenicillin., Del. Med. J; 1971, 43: 366.
213. Sinkula, A. A., and Lewis, C., Clinically useful antibiotics obtained by directed chemical
modification-lincomycins., J .Pharma. Sci; 1973, 62: 1757.
214. Bedford, C., Busfield, D., Child, K. J., Mac Gregor, J., Sutherland, P., and Tomich, E. G.,
Studies on the biological disposition of griseofulvin, an oral antifungal agent., Arch.
Dermantol; 1960, 81: 735.
215. Atkinson, R., Bedford, C., Child, K. J., and Tomich, E.G., Effect of Particle Size on
Blood Griseofulvin-Levels in Man., Nature (Lond.); 1962, 193: 588.
216. Shaw, T. R. D., and Careless, J. E., The effect of particle size on the absorption of
digoxin., Eur. J. Clin. Pharmacol; 1974, 7: 269.
217. Jounela, A. j., Pentikainen, P. J., and Sothmann, A., Effect of particle size on the
bioavailability of digoxin. Eur. J. Clin; 1975, 8; 365.
218. Finholt, P., Dissolution Technology (Leeson L J. and Carstensen J t. Eds) ., Academy of
Pharmaceutical Association Washington D C; 1974, p. 106-146.
219. Reinhold, J. G., Phillips, F. J., and Flippin, H. F., A comparison of the behavior of
microcrystalline sulfadiazine with that of ordinary. Amer. J. Med. Sci; 1945, 210: 141.
220. Finholt, P., and Solvang, S., Dissolution kinetics of drugs in human gastric juice: the role
of surface tension. J. Pharma.Sci; 1968, 57: 1322.
221. Newton, J., Rowley, G., and Tornblom, J., ketoprofe Invivo and Invitro absorption
Studies, J. Pharm. Pharmacol; 1971, 23: 1565.
222. Kakemi, K., Arita, T., and Muranishi, S., Absorption and excretion of drugs, Chem.
Pharm. Bull; 1965, 13: 976.
223. Jain, S. C., and Agrawal, G. P., Pharmacodynamic drug interaction of mexiletine with
tolbutamide in rats, Indian. Drugs; 1981, 19: 108.
224. Narurkar, A. N., and Jarowski, C. I.,Dissolution studies of Prednisolone., Drug Dev. Ind.
Pharm; 1983, 9: 999.
225. Mortada, L. M., and Mortada, S. A. M., Dissolution Studies of Sustained Release
Metformin Tablet., Acta. Pharm. Tech; 1982, 28: 297.
226. Monkhouse, D. C., and Lach, J. L., Use of adsorbents in enhancement of drug
dissolution. J. Pharm. Sci; 1972, 61: 1430.
227. Johansen, H., and Moller, N., Studies on microcrystalline cellulose. Arch Pharm Chem
Sci Ed; 1976, 4: 114.
228. Johanson, H., and Moller, N., Surface area stability of micronized steroids, Arch. Pharm.
Chem. Sci. Ed; 1977, 5: 171.
229. Mayersohn, M., and Gibaldi, M., New method of solid-state dispersion for increasing
dissolution rates, J. Pharm. Sci; 1966, 55: 1323.
230. Stupak, E. I., and Bates, T. R., dissolution of reserpine–polyvinylpyrrolidone
coprecipitates J. Pharm. Sci; 1972, 61: 400.
231. Kaur, R., Grant, D .J. W., and Eaves, T., Enhancement of dissolution rate of valdecoxib
by solid dispersions, J. Pharm. Sci; 1980, 69: 1317.
232. Sekiguchi, K., Obi, N., and Ueda, Y., Enhancement of Oral Bioavailability and Solid
Dispersion: A Review., Chem. Pharm. Bull; 1964, 12; 134.
233. The Biopharmaceutics classification system (BCS) guidance, Center for Drug Evaluation
and Research, US Food and Drug Administration; 2001, http://www.fda.gov/cder.
234. Loftsson T, Brewster ME., “Drug solublization and stabilization” J. Pharm. Science., 85:
1024-1074, 1996.
235. Loftsson T, Brewter ME., “Cyclodextrin as Pharmaceutical Excipients”. Pharma
Manager; 5, 22-31., 1997.
236. Szejtli, J., “Medicinal applications of cyclodextrins” Med. Res. Rev., 14, 353-386., 1994.
237. Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM: “Cyclodextrins in the
pharmaceutical field”. Drug Dev. Ind. Pharm. 17, 1503-1549., 1991.
238. Loftsson T, Brewster ME, “Pharmaceutical applications of cyclodextrins and Drug
solubilization and stabilization”., J. Pharm. Sci., 85(10): 1017-1025., 1996.
239. Szejtli, J., Akademiai, Kiado., “Cyclodextrins and their Inclusion complexes”, Budapest.
Hungary; Vol.12, p13. 1982.
240. Gandhi, R. B. and Karara, A. H., “Characterization, Dissolution and Diffusion Properties
of Tolbutamide-13-cyclodextrin Complex System”, Drug Dev. Ind. Pharm, 14:657.1988.
241. McCandless R, Yalkowsky SH. “Effect of hydroxypropyl-beta-cyclodextrin and pH on
the solubility of levemopamil HCl”, J. Pharm. Sci.; 87(12): 1639-42, 1998.
242. S.N. Luu, P.F. Carlier, P. Delort, J. Gazzola and D. Lafont, J. Pharm. Sci., 62, 452
(1973).
243. Khan, C.R. and Shechter, Y. and Goodman and Gilman’s; The Pharmacological basis
of Therapeutics, 8th
Edn., McGraw Hill, New York, 1712,1991.
244. S. Dhawan* and A.K. Singla., Performance Liquid Chromatographic Analysis of Glipizide:
Application to In Vitro and In Vivo Studies, J. Chromatogr. Sci., 2003, 41(6), 295-300.
top related